

The following listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (currently amended) A stable G-CSF formulation ~~having a residual ratio of G-CSF of 90% or more after long-term storage testing at 25°C for 3 months or a residual ratio of G-CSF of 90% or more after accelerated testing at 50°C for 1 month or a residual ratio of G-CSF of 90% or more after accelerated testing at 60°C for 2 weeks and a content of Met-oxidized G-CSF of 1% or less after accelerated testing at 50°C for 1 month or after accelerated testing at 60°C for 2 weeks.~~ containing one or more amino acids selected from the group consisting of lysine, histidine, arginine, aspartic acid, glutamic acid, threonine and asparagine; one or more amino acids selected from hydrophobic amino acids; and methionine.
2. (currently amended) The G-CSF formulation of ~~Claim~~claim 1 ~~containing one or more amino acids selected from the group consisting of lysine, histidine, arginine, aspartic acid, glutamic acid, threonine and asparagine; one or more amino acids selected from hydrophobic amino acids; and methionine.~~ having a residual ratio of G-CSF of 90% or more after long-term storage testing at 25°C for 3 months or a residual ratio of G-CSF of 90% or more after long-term storage testing at 40°C for 2 months or a residual ratio of G-CSF of 90% or more after accelerated testing at 50°C for 1 month or a residual ratio of G-CSF of 90% or more after accelerated testing at 60°C for 2 weeks and a content of Met-oxidized G-CSF of 1% or less after accelerated testing at 50°C for 1 month or after

accelerated testing at 60°C for 2 weeks, having a residual ratio of G-CSF of 90% or more after long-term storage testing at 25°C for 3 months or a residual ratio of G-CSF of 90% or more after long-term storage testing at 40°C for 2 months or a residual ratio of G-CSF of 90% or more after accelerated testing at 50°C for 1 month or a residual ratio of G-CSF of 90% or more after accelerated testing at 60°C for 2 weeks and a content of Met-oxidized G-CSF of 1% or less after accelerated testing at 50°C for 1 month or after accelerated testing at 60°C for 2 weeks.

3. (currently amended) The G-CSF formulation of ~~Claim 2~~claim 1 wherein said hydrophobic amino acid is selected from phenylalanine, tryptophan and leucine.
4. (currently amended) The G-CSF formulation of ~~Claim~~claim 1 containing one or more amino acids selected from the group consisting of lysine, histidine, arginine, aspartic acid and glutamic acid; one or more amino acids selected from the group consisting of phenylalanine, tryptophan and leucine; and methionine.
5. (currently amended) The G-CSF formulation of ~~Claim~~claim 1 containing phenylalanine, arginine and methionine.
6. (currently amended) The G-CSF formulation of ~~Claim~~claim 1, which is substantially free from protein as a stabilizer.

7. (currently amended) The G-CSF formulation of ~~Claim~~claim 1 in the form of a lyophilized formulation.
8. (currently amended) The G-CSF formulation of ~~Claim~~claim 1 further containing mannitol.
9. (currently amended) The G-CSF formulation of ~~Claim~~claim 1 further containing a surfactant.
10. (currently amended) The G-CSF formulation of ~~Claim~~claim 9 wherein said surfactant is a polyoxyethylene sorbitan alkyl ester.
11. (currently amended) The G-CSF formulation of ~~Claim~~claim 10 wherein said surfactant is Polysorbate 20 and/or 80.
12. (currently amended) The G-CSF formulation of ~~Claim~~claim 1, which has a pH of 5-7.
13. (currently amended) The G-CSF formulation of ~~Claim~~claim 12, which has a pH of 5.5-6.8.
14. (currently amended) The G-CSF formulation of ~~Claim~~claim 13, which has a pH of 6.5.

15. (currently amended) The G-CSF formulation of ~~Claim~~claim 1 wherein G-CSF is produced from CHO cells.
16. (currently amended) A stable G-CSF formulation having a residual ratio of G-CSF of 90% or more after long-term storage testing at 25°C for 3 months or a residual ratio of G-CSF of 90% or more after long-term storage testing at 40°C for 2 months or a residual ratio of G-CSF of 90% or more after accelerated testing at 50°C for 1 month or a residual ratio of G-CSF of 90% or more after accelerated testing at 60°C for 2 weeks, characterized in that it contains one or more amino acids selected from the group consisting of lysine, histidine, ~~arginine~~, aspartic acid, glutamic acid, threonine and asparagine; and one or more amino acids selected from hydrophobic amino acids; and it has a pH of 5-7.
17. (currently amended) A stable G-CSF formulation according to claim 16, characterized in that it contains one or more amino acids selected from the group consisting of lysine, histidine, ~~arginine~~, aspartic acid and glutamic acid; and one or more amino acids selected from the group consisting of phenylalanine, tryptophan and leucine; and it has a pH of 5-7.
18. (currently amended) The ~~G-CSF formulation of Claim 15, which has a pH of 6.5.~~ A stable G-CSF formulation having a residual ratio of G-CSF of 90% or more after long-term storage testing at 25°C for 3 months or a residual ratio of G-CSF of 90% or more after long-term storage testing at 40°C for 2 months or a residual ratio of G-CSF of 90%

or more after accelerated testing at 50°C for 1 month or a residual ratio of G-CSF of 90% or more after accelerated testing at 60°C for 2 weeks, characterized in that it contains one or more amino acids selected from the group consisting of lysine, histidine, arginine, aspartic acid, glutamic acid, threonine and asparagine; and one or more amino acids selected from the group consisting of tryptophan and leucine; and it has a pH of 5-7.

19. (currently amended) ~~A stabilized G-CSF formulation, which does not substantially produce a variant oxidized at methionine.~~ A stable G-CSF formulation according to claim 18, characterized in that it contains one or more amino acids selected from the group consisting of lysine, histidine, arginine, aspartic acid and glutamic acid; and one or more amino acids selected from the group consisting of tryptophan and leucine; and it has a pH of 5-7.
20. (currently amended) ~~A stabilized G-CSF formulation, which contains methionine and other one or more amino acids and does not substantially produce a variant oxidized at methionine.~~ The G-CSF formulation of claim 16 or 18, which has a pH of 6.5.
21. (currently amended) ~~The G-CSF formulation of Claim 19, which is substantially free of protein as a stabilizer.~~ A method for inhibiting a physiologically active protein containing a methionine residue from producing a variant oxidized at the methionine residue, comprising adding methionine to a composition containing said protein, wherein said physiologically active protein is PTH.

22. (currently amended) ~~A method for inhibiting a physiologically active protein containing a methionine residue from producing a variant oxidized at the methionine residue, comprising adding to a composition containing said protein.~~ The method of claim 21, wherein other proteins are not present as stabilizers.
23. (currently amended) ~~The method of Claim 22 wherein said physiologically active protein is a cytokine or a physiologically active peptide.~~ The method of claim 21, wherein said composition containing a physiologically active protein having a methionine residue is lyophilized or in the form of a solution.
24. (currently amended) ~~The method of Claim 22 wherein said physiologically active protein is a colony stimulating factor or PTH.~~ A stabilized composition containing a physiologically active protein having a methionine residue, further containing methionine and one or more other amino acids, wherein said physiologically active protein is PTH.
25. (currently amended) ~~The method of Claim 22 wherein said physiologically active protein is G-CSF, erythropoietin or PTH.~~ The composition of claim 24 wherein said amino acid is one or more selected from the group consisting of lysine, histidine, arginine, aspartic acid, glutamic acid, phenylalanine, tryptophan, leucine, isoleucine, valine, alanine, proline, glycine, serine, threonine, asparagine, glutamine and tyrosine.

26. (currently amended) ~~The method of Claim 22, wherein other proteins are not present as stabilizers.~~ The composition of claim 24, which is substantially free from other proteins as stabilizers.

Claims 27-30 have been canceled.